Stein O, Halperin G, Stein Y
Biochim Biophys Acta. 1980 Nov 7;620(2):247-60. doi: 10.1016/0005-2760(80)90206-4.
In vitro labeling of very low density lipoproteins (VLDL) with radioactive cholesteryl linoleyl ether, an analog of cholesteryl linoleate, was studied. The protocol which gave the highest efficiency and seemed least injurious to the final product included: (1) sonication of the labeled cholesteryl ether with partially delipidated high density lipoproteins (HDL); (2) transfer of the labeled lipids to VLDL in the presence of lipoprotein-deficient human serum; (3) reisolation of the VLDL by ultracentrifugation. Under optimal conditions 70% of the added labeled lipid was recovered with HDL and 60% were transferred from HDL to VLDL. The labeled cholesteryl linoleyl ether was shown to comigrate with the protein of VLDL on agarose gel electrophoresis. In negatively stained preparations, the labeled VLDl and its unlabeled counterpart had similar appearance. The in vitro labeled VLDL was injected into rats and was cleared from the circulation with a t1/2 comparable to endogenously labeled VLDL. More than 80% of the injected dose was recovered in the liver between 3 and 48 h after injection of VLDL labeled with [3H]cholesteryl linoleyl ether of which 91-97% were in the ether form. On radioautography of fixed frozen sections of liver the bulk of the radioautographic reaction was associated with the cytoplasm of hepatocytes. When the VLDL had been labeled also with [14C]cholesteryl linoleate only 35% of injected dose was present in the liver at 3 h, of which 87% was in unesterified form. The distribution of the labeled cholesteryl linoleyl ether, 3-48 h after injection, expressed as per cent of injected dose per organ was 0.7-1.5 in spleen, 0.2-0.5 in lung, 0.1 in heart and 0.2-0.4 in adrenal. The main advantage of the presently described approach in which a nondegradable analog of cholesteryl ester was introduced into VLDL by a biological procedure is the possibility to study the role of various organs to take up circulating cholesteryl ester, especially in species in which LDL is produced from VLDL.
研究了用放射性胆固醇亚油酰醚(胆固醇亚油酸酯的类似物)对极低密度脂蛋白(VLDL)进行体外标记。效率最高且似乎对最终产物损伤最小的方案包括:(1)将标记的胆固醇醚与部分脱脂的高密度脂蛋白(HDL)进行超声处理;(2)在缺乏脂蛋白的人血清存在下,将标记的脂质转移至VLDL;(3)通过超速离心重新分离VLDL。在最佳条件下,70%添加的标记脂质与HDL一起回收,60%从HDL转移至VLDL。标记的胆固醇亚油酰醚在琼脂糖凝胶电泳上显示与VLDL的蛋白质共同迁移。在负染制剂中,标记的VLDL及其未标记的对应物外观相似。将体外标记的VLDL注入大鼠体内,其从循环中清除的半衰期与内源性标记的VLDL相当。注射用[3H]胆固醇亚油酰醚标记的VLDL后3至48小时内,超过80%的注射剂量在肝脏中回收,其中91 - 97%为醚形式。在肝脏固定冰冻切片的放射自显影片上,大部分放射自显影反应与肝细胞的细胞质相关。当VLDL也用[14C]胆固醇亚油酸酯标记时,注射后3小时肝脏中仅存在35%的注射剂量,其中87%为未酯化形式。注射后3 - 48小时,标记的胆固醇亚油酰醚在各器官中的分布,以注射剂量的百分比表示,脾脏为0.7 - 1.5,肺为0.2 - 0.5,心脏为0.1,肾上腺为0.2 - 0.4。目前所描述方法的主要优点是通过生物学程序将胆固醇酯的不可降解类似物引入VLDL,从而有可能研究各器官在摄取循环胆固醇酯中的作用,特别是在由VLDL产生低密度脂蛋白(LDL)的物种中。